Dr. Matthew Clavenna, MD

Dr. Clavenna practices at Ear, Nose & Throat Associates in Clearwater, Florida.

Dr. Clavenna's NPI, 1043453350, was assigned on April 16, 2009. Dr. Clavenna graduated from LSU Health Shreveport School of Medicine in 2009. Dr. Clavenna holds Florida license ME128445.

Dr. Clavenna's primary practice is Ear, Nose & Throat Associates, at 3190 N McMullen Booth Rd, Clearwater, FL 33761 in Pinellas County. The practice phone is (727) 216-0700.

Dr. Clavenna's primary practice is Ear, Nose & Throat Associates in Clearwater, Florida. Dr. Clavenna is also affiliated with Morton Plant Hospital. The medical group on file is Ear, Nose & Throat Associates. Dmand AI also links Dr. Clavenna to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Clavenna practices, 4 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Clavenna's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Clavenna is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Clavenna's licenses on file in 4 states: Florida, Arizona, Tennessee and Louisiana.

Dmand AI lists acute sinusitis, chronic ear infection, chronic nasal allergies, chronic sinusitis, ear eustachian tube disorders, endoscopic sinus surgery, hearing loss and impairment and larynx and vocal cord disease among the conditions Dr. Clavenna treats.

CMS data shows 2,284 Medicare services from Dr. Clavenna across 20 procedure codes in 2024, for 683 Medicare patients. Medicare paid $200,134 for them.

CMS counts 683 Medicare patients who saw Dr. Clavenna in 2024. The largest group is 75 to 84, with 281 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Clavenna's median patient age at 70, with 57% women.

In 2024, Dr. Clavenna wrote 1,791 Medicare Part D claims for 580 patients. 97% of them were for generic drugs. CMS names the drug for 1,676 of them, across 24 drugs with 11 or more claims each, at $42,784 in total drug cost. In 2023, CMS named 1,461 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Clavenna for performance year 2024, reported individually. Dr. Clavenna accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 6 papers to Dr. Clavenna, published from 2015 to 2016. 2015 was the busiest year, with 3. The most frequent topics are Sinusitis, Anti-Asthmatic Agents and Omalizumab. Dr. Clavenna's most frequent co-authors are Rakesh Chandra, MD, Paul T. Russell, MD and Simpson Bobo Tanner, MD.

CMS Open Payments shows 68 general payments to Dr. Clavenna from 25 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 85% of the total. Medtronic USA, Inc. paid the most, $278.

Dmand AI lists 2 awards for Dr. Clavenna, most recently Member in 2008.

Dr. Clavenna graduated from LSU Health Shreveport School of Medicine in 2009. Dr. Clavenna is a member of NHS.

Dr. Clavenna is in network with 18 carriers, including Aetna, United Healthcare and Cigna. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.